Normunity is pioneering cancer-fighting medicines that target novel immuno-oncology mechanisms.
Location: United States, Connecticut, West Haven
Total raised: $140M
Investors 3
| Date | Name | Website |
| - | Connecticu... | ctinnovati... |
| 10.11.2022 | Taiho Vent... | taihoventu... |
| 10.11.2022 | Canaan Par... | canaan.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.01.2025 | Series B | $75M | - |
| 25.10.2022 | Series A | $65M | - |
Mentions in press and media 6
| Date | Title | Description |
| 14.01.2025 | Normunity Secures $75 Million to Revolutionize Cancer Treatment | In the ever-evolving landscape of biotechnology, Normunity stands out like a lighthouse in a storm. The Boston and New Haven-based company has just raised $75 million in a Series B funding round, a significant boost for its mission to devel... |
| 13.01.2025 | Normunity: $75 Million (Series B) Raised For Broadening Pipeline Of Novel Anti-Cancer Therapies | Normunity, a biotechnology company creating novel anti-cancer therapies, announced today that it closed a Series B funding round of $75 million. The funding was co-led by Samsara BioCapital and Enavate Sciences, alongside other new investor... |
| 13.01.2025 | Normunity Raises $75M in Series B Funding | Normunity, a Boston, MA- and New Haven, CT-based biotechnology company developing new anti-cancer therapies, raised $75M in Series B funding. The round was led by Samsara BioCapital and Enavate Sciences, alongside other new investors Regene... |
| 25.10.2022 | Normunity Raises $65M in Series A Financing | Normunity, a Boston, MA and West Haven, CT-based biotechnology company, raised $65M in Series A funding. The round was led by Canaan Ventures with participation from Sanofi Ventures, Taiho Ventures and Osage University Partners. The company... |
| 25.10.2022 | Normunity launches with $65 million to unleash the immune system on tumors | Our best weapon against cancer may already live inside us — it just needs a little prodding. That’s the premise behind Normunity, which launched Tuesday with $65 million from investors to develop a suite of drugs that it dubs “immune normal... |
| - | Normunity | “We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.” |